- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03966794
Functional Scaffold Transplantation Combined With Epidural Electrical Stimulation for Spinal Cord Injury Repair
October 31, 2019 updated by: Jianwu Dai, Chinese Academy of Sciences
Safety and Efficacy of Functional Neural Regeneration Collagen Scaffold Transplantation Combined With Epidural Electrical Stimulation for Spinal Cord Injury Repair
The study is designed to assess the role of functional neural regeneration collagen scaffold transplantation combined with epidural electrical stimulation in spinal cord injury patients.
Study Overview
Status
Unknown
Conditions
Study Type
Interventional
Enrollment (Anticipated)
9
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tianjin, China, 300162
- Recruiting
- Affiliated Hospital of Logistics Universtiy of CAPF
-
Contact:
- Fengwu Tang
-
Contact:
- Shixiang Cheng
- Email: shixiangcheng@vip.126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
The enrolled participants are divided into three categories:
- Participants had complete functional scaffold transplantation in previous study and had motor functional recovery
- Participants With Acute Complete SCI: (1) Classification ASIA A, occurring within past 14 days; (2) Completely spinal cord injury at neurological level C4- T12/L1; (3) No serious complications
- Participants With Chronic Complete SCI: (1) Classification ASIA A, greater than 6 months post injury and no significant further improvement within past 3 months; (2) Completely spinal cord injury at neurological level C4- T12/L1; (3) Peripheral nervous system in good condition; (4) No serious complications
Inclusion Criteria For All The Participants
- Men or non-pregnant women, 18-60 years old
- Ability and willingness to regular visit to hospital and follow up during the protocol Procedures
- Accompanied by a family member
- Signed informed consent
Exclusion Criteria:
- Obvious muscle atrophy or fibrosis
- Decline in peripheral nerve function
- A current diagnosis of diseases affecting spinal cord injury recovery or rehabilitation training (e.g., brain injury, cerebral hemorrhage, cognitive impairment, other central nervous system diseases)
- Having serious health problems, (e.g., cardiovascular disease, diabetes, autoimmune diseases, tumors or severe hypertension) or serious complications (e.g. severe bedsores, pulmonary infection, respiratory disorders)
- Pregnancy or lactation
- History of mental illness or suicide risk, with a history of epilepsy or other central nervous system disorders
- No family member accompany or can not get in touch with family members
- Poor compliance, difficult to complete the study
- Any other conditions that might increase the risk of participants or interfere with the clinical trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Epidural Electrical Stimulation
|
Participants had finished the previous clinical trial with functional neural regeneration collagen scaffold transplantation, and will receive epidural electrical stimulation of the spinal cord in this group.
|
|
Experimental: Functional scaffold & Epidural Electrical Stimulation
|
Participants with acute complete SCI or chronic complete SCI will receive functional neural regeneration scaffold transplantation and epidural electrical stimulation of the spinal cord.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety and Tolerability assessed by Adverse Events
Time Frame: Up to 6 months
|
Proportion of patients with postoperative infections and serious adverse events (SAEs) will be assessed by long term follow-up
|
Up to 6 months
|
|
Change in ASIA Impairment Scale
Time Frame: Baseline, 1, 3 , 6, 12 and 24 months post-treatment
|
American Spinal Injury Association Impairment Scale of A, B, C, D or E will be assessed before and after transplantation.
|
Baseline, 1, 3 , 6, 12 and 24 months post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in ASIA motor score
Time Frame: Baseline, 1, 3 , 6, 12 and 24 months post-treatment
|
Baseline, 1, 3 , 6, 12 and 24 months post-treatment
|
|
Change in Functional Independence Measure (FIM)
Time Frame: Baseline, 1, 3 , 6, 12 and 24 months post-treatment
|
Baseline, 1, 3 , 6, 12 and 24 months post-treatment
|
|
Change in Somatosensory Evoked Potentials (SSEP) monitoring
Time Frame: Baseline, 1, 3 , 6, 12 and 24 months post-treatment
|
Baseline, 1, 3 , 6, 12 and 24 months post-treatment
|
|
Change in Motor Evoked Potentials (MEP) monitoring
Time Frame: Baseline, 1, 3 , 6, 12 and 24 months post-treatment
|
Baseline, 1, 3 , 6, 12 and 24 months post-treatment
|
|
Changes at the Transplantation Site in Spinal Cord by Magnetic Resonance Imaging (MRI)
Time Frame: Baseline, 1, 3 , 6, 12 and 24 months post-treatment
|
Baseline, 1, 3 , 6, 12 and 24 months post-treatment
|
|
Change in Walking Speed
Time Frame: Baseline, 1, 3 , 6, 12 and 24 months post-treatment
|
Baseline, 1, 3 , 6, 12 and 24 months post-treatment
|
|
Change in Stride length
Time Frame: Baseline, 1, 3 , 6, 12 and 24 months post-treatment
|
Baseline, 1, 3 , 6, 12 and 24 months post-treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2019
Primary Completion (Anticipated)
December 1, 2021
Study Completion (Anticipated)
December 1, 2021
Study Registration Dates
First Submitted
May 23, 2019
First Submitted That Met QC Criteria
May 28, 2019
First Posted (Actual)
May 29, 2019
Study Record Updates
Last Update Posted (Actual)
November 1, 2019
Last Update Submitted That Met QC Criteria
October 31, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAS-XDA-EESCI/IGDB
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.